Clinical Trial Update: The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation [Phase 4]

View source ↗

Summary

Clinical trial update on using tocilizumab for severe COVID-19 with suspected pulmonary hyperinflammation (Phase 4).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Covid19 Pneumonia | Phase 4 | Status: UNKNOWN